Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Vasculitis induced by tumor necrosis factor-targeted therapies.

Literature DB >> 19007533

Vasculitis induced by tumor necrosis factor-targeted therapies.

Manuel Ramos-Casals¹, Pilar Brito-Zerón, Maria-Jose Cuadrado, Munther A Khamashta.

Abstract

Tumor necrosis factor (TNF)-targeted therapies are increasingly used for a rapidly expanding number of rheumatic and autoimmune diseases. With this use and longer follow-up periods of treatment, there are a growing number of reports of the development of autoimmune processes related to these new therapeutic agents. We have analyzed the clinical characteristics, outcomes, and patterns of association with the different anti-TNF agents used in all reports of vasculitis developed after TNF-targeted therapy. A total of 132 cases, identified up to July 2008, are included and analyzed in this review.

Entities: Disease Gene

Mesh：

Substances：

Year: 2008 PMID： 19007533 DOI： 10.1007/s11926-008-0072-z

Source DB: PubMed Journal: Curr Rheumatol Rep ISSN： 1523-3774 Impact factor: 4.592

53 in total

1. Cutaneous vasculitis and glomerulonephritis in a patient taking the anti-TNF alpha agent etanercept for rheumatoid arthritis.

Authors: Christian Hubert Roux; Olivier Brocq; Véronique Albert C Breuil; Liana Euller-Ziegler
Journal: Joint Bone Spine Date: 2004-09 Impact factor: 4.929

2. Multifocal motor neuropathy during treatment with infliximab.

Authors: Dario Cocito; Bruno Bergamasco; Alessia Tavella; Fabio Poglio; Ilaria Paolasso; Paolo Costa; Palma Ciaramitaro; Gianluca Isoardo
Journal: J Peripher Nerv Syst Date: 2005-12 Impact factor: 3.494

3. Henoch Schönlein purpura following etanercept treatment of rheumatoid arthritis.

Authors: T N Duffy; M Genta; S Moll; P-Y Martin; C Gabay
Journal: Clin Exp Rheumatol Date: 2006 Mar-Apr Impact factor: 4.473

4. Vasculitis in systemic lupus erythematosus: prevalence and clinical characteristics in 670 patients.

Authors: Manuel Ramos-Casals; Norma Nardi; Mariana Lagrutta; Pilar Brito-Zerón; Albert Bové; German Delgado; Ricard Cervera; Miguel Ingelmo; Josep Font
Journal: Medicine (Baltimore) Date: 2006-03 Impact factor: 1.889

5. Neuropathy resembling CIDP in patients receiving tumor necrosis factor-alpha blockers.

Authors: C Richez; P Blanco; A Lagueny; T Schaeverbeke; J Dehais
Journal: Neurology Date: 2005-04-26 Impact factor: 9.910

6. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.

Authors: N Mohan; E T Edwards; T R Cupps; P J Oliverio; G Sandberg; H Crayton; J R Richert; J N Siegel
Journal: Arthritis Rheum Date: 2001-12

Review 7. C-ANCA positive systemic vasculitis in a patient with rheumatoid arthritis treated with infliximab.

Authors: Dayavathi Ashok; Shirish Dubey; Ian Tomlinson
Journal: Clin Rheumatol Date: 2007-08-22 Impact factor: 2.980

8. Antineutrophil cytoplasmic antibody-associated necrotizing crescentic glomerulonephritis in a patient receiving treatment with etanercept for severe rheumatoid arthritis.

Authors: T W R Doulton; B Tucker; J Reardon; N Velasco
Journal: Clin Nephrol Date: 2004-09 Impact factor: 0.975

9. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases.

Authors: Manuel Ramos-Casals; Pilar Brito-Zerón; Sandra Muñoz; Natalia Soria; Diana Galiana; Laura Bertolaccini; Maria-Jose Cuadrado; Munther A Khamashta
Journal: Medicine (Baltimore) Date: 2007-07 Impact factor: 1.889

10. Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series.

Authors: Stephen J Jarrett; Gaye Cunnane; Philip G Conaghan; Sarah J Bingham; Maya H Buch; Mark A Quinn; Paul Emery
Journal: J Rheumatol Date: 2003-10 Impact factor: 4.666

13 in total

Review 1. Paradoxical inflammation induced by anti-TNF agents in patients with IBD.

Authors: Isabelle Cleynen; Séverine Vermeire
Journal: Nat Rev Gastroenterol Hepatol Date: 2012-07-03 Impact factor: 46.802

2. Henoch-Schönlein purpura complicating adalimumab therapy for Crohn's disease.

Authors: Farooq Z Rahman; Gagandeep K Takhar; Ovishek Roy; Anna Shepherd; Stuart L Bloom; Sara A McCartney
Journal: World J Gastrointest Pharmacol Ther Date: 2010-10-06

3. Etanercept treatment-related c-ANCA-associated large vessel vasculitis.

Authors: Shira Ginsberg; Itzhak Rosner; Gleb Slobodin; Nina Boulman; Michael Rozenbaum; Lisa Kaly; Ofrat Katz Beyar; Doron Rimar
Journal: Clin Rheumatol Date: 2015-12-01 Impact factor: 2.980

Review 4. ANCA-associated vasculitis in a patient with enteropathic spondylarthritis: a case report and literature review.

Authors: Francisca Guimarães; Daniela Santos-Faria; Soraia Azevedo; Joana Ramos Rodrigues; Joana Leite Silva; Diogo Esperança-Almeida; Bárbara Ribeiro; Raquel Vaz; Filipa Teixeira; José Tavares-Costa; Carmo Afonso; Daniela Peixoto
Journal: Clin Rheumatol Date: 2021-01-30 Impact factor: 2.980

Review 5. Monoclonal antibody therapy-associated neurological disorders.

Authors: Xavier Bosch; Albert Saiz; Manuel Ramos-Casals
Journal: Nat Rev Neurol Date: 2011-01-25 Impact factor: 42.937

6. Tumor necrosis factor-alpha (TNF-α)-blockade-induced hepatic sarcoidosis in psoriatic arthritis (PsA): case report and review of the literature.

Authors: Raquel Cuchacovich; Joseph Hagan; Tahir Khan; Arthur Richert; Luis R Espinoza
Journal: Clin Rheumatol Date: 2010-10-01 Impact factor: 2.980

Vasculitis induced by tumor necrosis factor-targeted therapies.

1. Cutaneous vasculitis and glomerulonephritis in a patient taking the anti-TNF alpha agent etanercept for rheumatoid arthritis.

2. Multifocal motor neuropathy during treatment with infliximab.

3. Henoch Schönlein purpura following etanercept treatment of rheumatoid arthritis.

4. Vasculitis in systemic lupus erythematosus: prevalence and clinical characteristics in 670 patients.

5. Neuropathy resembling CIDP in patients receiving tumor necrosis factor-alpha blockers.

6. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.

Review 7. C-ANCA positive systemic vasculitis in a patient with rheumatoid arthritis treated with infliximab.

8. Antineutrophil cytoplasmic antibody-associated necrotizing crescentic glomerulonephritis in a patient receiving treatment with etanercept for severe rheumatoid arthritis.

9. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases.

10. Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series.

Review 1. Paradoxical inflammation induced by anti-TNF agents in patients with IBD.

2. Henoch-Schönlein purpura complicating adalimumab therapy for Crohn's disease.

3. Etanercept treatment-related c-ANCA-associated large vessel vasculitis.

Review 4. ANCA-associated vasculitis in a patient with enteropathic spondylarthritis: a case report and literature review.

Review 5. Monoclonal antibody therapy-associated neurological disorders.

6. Tumor necrosis factor-alpha (TNF-α)-blockade-induced hepatic sarcoidosis in psoriatic arthritis (PsA): case report and review of the literature.

Review 7. TNFR2 Costimulation Differentially Impacts Regulatory and Conventional CD4⁺ T-Cell Metabolism.

8. Adalimumab induced pulmonary sarcoid reaction.

9. Effect of tumor necrosis factor inhibitors on rheumatoid arthritis-induced peripheral neuropathy: A cohort study.

Review 10. Drug-Induced Vasculitis: New Insights and a Changing Lineup of Suspects.

Review 7. C-ANCA positive systemic vasculitis in a patient with rheumatoid arthritis treated with infliximab.

Review 1. Paradoxical inflammation induced by anti-TNF agents in patients with IBD.

Review 4. ANCA-associated vasculitis in a patient with enteropathic spondylarthritis: a case report and literature review.

Review 5. Monoclonal antibody therapy-associated neurological disorders.

Review 7. TNFR2 Costimulation Differentially Impacts Regulatory and Conventional CD4+ T-Cell Metabolism.

Review 10. Drug-Induced Vasculitis: New Insights and a Changing Lineup of Suspects.

Review 7. TNFR2 Costimulation Differentially Impacts Regulatory and Conventional CD4⁺ T-Cell Metabolism.